BPC-157 demonstrates exceptional safety in animal toxicology studies, with comprehensive evaluations in mice, rats, rabbits, and dogs failing to establish a lethal dose (LD) across wide dose ranges extending from standard research doses (6 g/kg) to levels exceeding 1000-fold higher concentrations (20 mg/kg), with no evidence of acute toxicity, organ-specific damage, or systemic adverse effects even following repeated high-dose administration
It also plays an essential role in tissue building and repair and can be beneficial for those with liver damage (Anderson, 1998)
therapy requires trained medical personnel for administration, thus raising costs, patient burden for clinic visits, and risk of discomfort and phlebitis
In human clinical use, reported side effects are generally mild and transient: Mild injection site redness or discomfort (resolves within hours) Transient nausea in some patients, particularly early in the protocol Mild dizziness or light-headedness (rare, typically dose-related) Temporary fatigue in the first few days (often a sign of active tissue remodeling) No significant systemic toxicity, organ damage, hormonal suppression, or addiction potential has been documented in the published literature
How does GHK-CU dosing compare to BPC-157 or TB-500
Results vary depending on your starting levels and health goals
